Search Results | Blood | American Society of Hematology

1-20 of 94

Sort by

Sort Order Select

Journal Articles

Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines

Monia Marchetti, Annalisa Chiappella, Maria Guarino, Giorgia Gobbi, Massimo Martino, Andrés J.M. Ferreri, Luca Fumagalli, Riccardo Saccardi, Mauro Montanari, Maurizio Martelli, Francesco Merli, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 5056–5057.

DOI: https://doi.org/10.1182/blood-2022-165125

Published: 2022

Journal Articles

A 7-Gene Signature in Unmanipulated Leukaphereses Correlates with in-Vivo CAR T-Cell Expansion and Survival of Lymphoma Patients Receiving Tisagenlecleucel or Axicabtagene Ciloleucel Therapy

Cristiana Carniti, Nicole Caldarelli, Francesca Nanetti, Martina Magni, Emma Esposito, Tommaso Torelli, Luca Agnelli, Silvia Brich, Chiara Monfrini, Eugenio Fardella, Paolo Longoni, Daniele Lorenzini, Martina Pennisi, Annalisa Chiappella, Paolo Corradini

Blood (2022) 140 (Supplement 1): 641–643.

DOI: https://doi.org/10.1182/blood-2022-168796

Published: 2022

Journal Articles

Non-Restrictive Diet Does Not Increase Infections in Patients with Neutropenia after Stem Cell Transplantation: Final Analysis of the Neutrodiet Multicenter, Randomized Trial

Federico Stella, Vincenzo Marasco, Giorgia Virginia Levati, Cecilia Vismara, Anna Guidetti, Annalisa Chiappella, Giulia Perrone, Cristina Tecchio, Nicola Mordini, Martina Pennisi, Giorgia Ferrara, Giorgia Gobbi, Lucia Saracino, Cristiana Carniti, Paolo Corradini

Blood (2022) 140 (Supplement 1): 417–419.

DOI: https://doi.org/10.1182/blood-2022-158662

Published: 2022

Journal Articles

Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

Umberto Vitolo, Grzegorz S. Nowakowski, John M. Burke, Christopher P. Fox, Marek Trneny, Annalisa Chiappella, Maeve Waldron-Lynch, Steve Wagner, Alok Pachori, Georg Lenz

Blood (2022) 140 (Supplement 1): 6618–6620.

DOI: https://doi.org/10.1182/blood-2022-155995

Published: 2022

Journal Articles

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Blood (2022) 140 (Supplement 1): 6538–6539.

DOI: https://doi.org/10.1182/blood-2022-163824

Published: 2022

Journal Articles

Patients Outcome after Chimeric Antigen Receptor (CAR) T-Cells Failure in Aggressive B-Cell Lymphomas: Role of Immunotherapy and Prognostic Factors

Anna Dodero, Stefania Bramanti, Martina Pennisi, Silva Ljevar, Annalisa Chiappella, Massimo Magagnoli, Anna Guidetti, Francesco Corrado, Paulina Nierychlewska, Alice Di Rocco, Antonello Domenico Cabras, Daoud Rahal, Chiara De Philippis, Armando Santoro, Carmelo Carlo-Stella, Paolo Corradini

Blood (2022) 140 (Supplement 1): 9468–9469.

DOI: https://doi.org/10.1182/blood-2022-163651

Published: 2022

Journal Articles

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Blood (2022) 140 (17): 1907–1916.

DOI: https://doi.org/10.1182/blood.2022015560

Published: 2022

Includes: Supplemental data

Journal Articles

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Blood (2021) 138 (Supplement 1): 134.

DOI: https://doi.org/10.1182/blood-2021-153680

Published: 2021

Journal Articles

Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Gloria Iacoboni, Kai Rejeski, Lina Camacho, Annalisa Chiappella, Serafina Guadagnuolo, Lucía López Corral, Mariana Bastos-Oreiro, Javier Delgado Serrano, Christian Schmidt, Cecilia Carpio, Juan Luis Reguera, Mi Kwon, Alejandro Martín García-Sancho, Pier Luigi Zinzani, Paolo Corradini, Marion Subklewe, Pere Barba

Blood (2021) 138 (Supplement 1): 2827.

DOI: https://doi.org/10.1182/blood-2021-153087

Published: 2021

Journal Articles

Tisagenlecleucel and Axicabtagene Ciloleucel Expansion Kinetics and CAR T Cell Attributes in the Infusion Products Are Early Predictors of Clinical Efficacy

Cristiana Carniti, Chiara Monfrini, Vanessa Aragona, Martina Magni, Cristina Vella, Eugenio Fardella, Riccardo Betta, Anisa Bermema, Federico Stella, Anna Dodero, Annalisa Chiappella, Anna Guidetti, Paolo Corradini

Blood (2021) 138 (Supplement 1): 3877.

DOI: https://doi.org/10.1182/blood-2021-152309

Published: 2021

Journal Articles

Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem

Blood (2021) 138 (Supplement 1): 3867.

DOI: https://doi.org/10.1182/blood-2021-154037

Published: 2021

Journal Articles

A Novel Method for Molecular Enumeration of Circulating Tisa-Cel and Axi-Cel in Lymphoma Patients

Chiara Monfrini, Vanessa Aragona, Martina Magni, Riccardo Betta, Cristina Vella, Chiara Paolizzi, Anna Dodero, Annalisa Chiappella, Anna Guidetti, Paolo Corradini, Cristiana Carniti

Blood (2020) 136 (Supplement 1): 48–49.

DOI: https://doi.org/10.1182/blood-2020-141314

Published: 2020

Journal Articles

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Carola Boccomini, MD, Marie José Kersten, MD PhD, Annalisa Chiappella, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Mei Hentrup, BSN, BS, So Hyun Rhee, PharmD, Patrick Hagner, PhD, Christian Klein, PhD, Michael Pourdehnad, Kristen Hege, MD, Juergen Dobmeyer, MD, Zariana Nikolova, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 41–42.

DOI: https://doi.org/10.1182/blood-2020-134949

Published: 2020

Journal Articles

Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting

Annalisa Chiappella, Anna Dodero, Anna Guidetti, Filippo Bagnoli, MD, Vanessa Aragona, Anna Maria Barbui, MD, Stefania Bramanti, MD, Matteo Giovanni Carrabba, MD, Federica Sorà, MD, Pierluigi Zinzani, Prof, MD, Chiara Monfrini, Cristiana Carniti, Paolo Corradini

Blood (2020) 136 (Supplement 1): 12–13.

DOI: https://doi.org/10.1182/blood-2020-140054

Published: 2020

Journal Articles

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R 2 -CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Blood (2019) 134 (Supplement_1): 3475.

DOI: https://doi.org/10.1182/blood-2019-123948

Published: 2019

Journal Articles

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

Blood (2019) 134 (Supplement_1): 398.

DOI: https://doi.org/10.1182/blood-2019-123027

Published: 2019

Journal Articles

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Blood (2019) 134 (Supplement_1): 4092.

DOI: https://doi.org/10.1182/blood-2019-123083

Published: 2019

Journal Articles

The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Blood (2019) 134 (Supplement_1): 2025.

DOI: https://doi.org/10.1182/blood-2019-130786

Published: 2019

Journal Articles

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Blood (2018) 132 (Supplement 1): 401.

DOI: https://doi.org/10.1182/blood-2018-99-110289

Published: 2018

Journal Articles

Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified

Francesco Maura, Niccolò Bolli, Daniel Leongamornlert, BS, Cristiana Carniti, Anna Dodero, MD, Federico Abascal, Adele Testi, Bernardo Rodriguez-Martin, Alessio Pellegrinelli, Giulia Biancon, Martina Magni, Annalisa Chiappella, MD, Inigo Martincorena, Jose M. C. Tubio, Giancarlo Pruneri, Peter J. Campbell, PhD, Paolo Corradini, MD

Blood (2018) 132 (Supplement 1): 4115.

DOI: https://doi.org/10.1182/blood-2018-99-112094

Published: 2018

NARROW

Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines

A 7-Gene Signature in Unmanipulated Leukaphereses Correlates with in-Vivo CAR T-Cell Expansion and Survival of Lymphoma Patients Receiving Tisagenlecleucel or Axicabtagene Ciloleucel Therapy

Non-Restrictive Diet Does Not Increase Infections in Patients with Neutropenia after Stem Cell Transplantation: Final Analysis of the Neutrodiet Multicenter, Randomized Trial

Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Patients Outcome after Chimeric Antigen Receptor (CAR) T-Cells Failure in Aggressive B-Cell Lymphomas: Role of Immunotherapy and Prognostic Factors

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Tisagenlecleucel and Axicabtagene Ciloleucel Expansion Kinetics and CAR T Cell Attributes in the Infusion Products Are Early Predictors of Clinical Efficacy

Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem

A Novel Method for Molecular Enumeration of Circulating Tisa-Cel and Axi-Cel in Lymphoma Patients

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only